- €72.93m
- €70.77m
- €10.97m
Brief: Nexstim Agrees On Loan With Finnvera
Brief: Health Canada Approves Nexstim NBS 6 System For Treatment Of MDD
Brief: Nexstim Gets NBS 6 System Order From Clinic In Florida, US
Brief: Nexstim Oyj Says To Launch A New Stock Option Plan 2024H
Brief: Nexstim Receives NBS System 5 Order From Neurosurgery Customer In Germany
Brief: Nexstim H2 EBITDA Swings To Profit Of EUR 0.6 Million
Brief: Nexstim Receives NBS System 5 Order In US
Brief: Nexstim Specifies Its Guidance For 2023
Brief: Nexstim Gets Nexstim NBS System 5 Order From Distributor In Europe
Brief: Nexstim Gets Nexstim NBS System 5 Order
Brief: Nexstim Gets Order For Two Nbs 6 Systems
Brief: Nexstim Gets NBS System 6 Order From Hospital In United States
Brief: Nexstim Gets First Order For NBS 6 Therapy System In US
Brief: Nexstim Targets Positive EBITDA For 2023
Brief: Nexstim Wins Tender Process
Brief: Nexstim Receives NBS System 5 Order In Europe
Brief: Nexstim Receives Order For NBS 5 System With Nexspeech
Brief: Nexstim Delivers Nbs 5+ System To New Customer
Brief: Nexstim H1 Operating Result Swings To Loss EUR 1.4 Mln